switching between glp-1 agonists chart dose conversion and safe guide GLP-1 analog dosing chart
Description
The development of dual GIPRGLP1R coagonists that bind to either one or the other receptor (sequence-mixed dual agonists) has emerged as an innovative therapeutic strategy for obesity and type 2 diabetes
Earlier this year, Blue Cross Blue Shield said five GLP-1 drugs now account for nearly 20% of its pharmacy spend.
In clinical trials, it led to a weight reduction of up to 16.2%
The dual GIP/GLP-1 receptor agonist tirzepatide is among the furthest developed multi-agonists for diabetes care and has so far displayed promising nephroprotective effects
Supports overall daily wellness
Learn more about your weight loss options as a senior on Medicare here.
